Association of Favorable Cerebrospinal Fluid Markers With Reversion of Mild Cognitive Impairment Due to Parkinson’s Disease
PD-MCI reverters may have a more favorable trajectory in terms of AD pathology relative to PD-MCI nonreverters. Future studies are needed to verify whether PD-MCI reversion may represent an intermediate prognostic group between CN individuals and those with MCI nonreversion.
Authors
- Lea Hemphill
- Rhiannon Rivas (ORCID: https://orcid.org/0000-0002-2340-541X)
- Khashayar Dashtipour (ORCID: https://orcid.org/0000-0003-3547-0443)
- Jacob D. Jones (ORCID: https://orcid.org/0000-0003-3544-7294)
- Cameron A. Ryczek
- Zackary Zanotelli
- Nicholas Renteria
Institutions
- Loma Linda University (US)
- University Health System (US)
Publication Details
- Journal
- Journal of Neuropsychiatry
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1176/appi.neuropsych.20240099
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Neurocrine Biosciences
- Verily Life Sciences
- Voyager Therapeutics
- Servier
- H. Lundbeck A/S
- Sun Pharma
- National Institutes of Health
- Genentech
- Allergan
- Avid Radiopharmaceuticals